A transat­lantic biotech flags a painful PhI­II can­cer flop, wav­ing a white flag

More than 4 years af­ter lit­tle Ery­tech in­flat­ed some rare pas­sion for its stock with up­beat Phase IIb da­ta for their lead drug in pan­cre­at­ic can­cer, they’ve let the air out of the par­ty bal­loons.

The transat­lantic biotech $ERYP put the word out Mon­day morn­ing that its drug eryas­pase flopped in a Phase III piv­otal for sec­ond line metasta­t­ic pan­cre­at­ic can­cer, slam­ming its stock, which plunged more than 30%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER